Elsayed Soliman to Lisinopril
This is a "connection" page, showing publications Elsayed Soliman has written about Lisinopril.
Connection Strength
0.398
-
Dewland TA, Soliman EZ, Yamal JM, Davis BR, Alonso A, Albert CM, Simpson LM, Haywood LJ, Marcus GM. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Circ Arrhythm Electrophysiol. 2017 Dec; 10(12).
Score: 0.155
-
Soliman EZ, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, Jayasingne IK, Furberg CD. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials. 2011 Jan 05; 12:3.
Score: 0.096
-
Bang CN, Soliman EZ, Simpson LM, Davis BR, Devereux RB, Okin PM. Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. Am J Hypertens. 2017 Sep 01; 30(9):914-922.
Score: 0.038
-
Haywood LJ, Davis BR, Piller LB, Simpson LM, Ghosh A, Einhorn PT, Ford CE, Probstfield JL, Soliman EZ, Wright JT. Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT. J Natl Med Assoc. 2018 Aug; 110(4):343-351.
Score: 0.038
-
Ernst ME, Davis BR, Soliman EZ, Prineas RJ, Okin PM, Ghosh A, Cushman WC, Einhorn PT, Oparil S, Grimm RH. Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Am Soc Hypertens. 2016 12; 10(12):930-938.e9.
Score: 0.036
-
Dewland TA, Soliman EZ, Davis BR, Magnani JW, Yamal JM, Piller LB, Haywood LJ, Alonso A, Albert CM, Marcus GM. Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease. JAMA Intern Med. 2016 08 01; 176(8):1085-92.
Score: 0.035